TL
Telix Pharmaceuticals Limited
TLX · NASDAQ
$11.95 +0.17% (+$0.02)
1M +2.31%
Market Cap $5.69B
P/E Ratio -
Div. Yield -
ROE 1.68%
Bulios Fair Price
$10.4
13.0% downside
Current Price
$11.95
Undervalued Fair Value Overvalued
According to Bulios Fair Price, TLX is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
4/9Valuation
8 /100
Expensive EV/EBITDA 78.44x
P/B 9.14x
P/S 4.72x
Growth
100 /100
Growing Rev. growth 96.00%
Book val. growth 98.13%
EPS growth N/A
Profitability
23 /100
Weak Gross margin 53.11%
FCF margin 6.87%
Net margin 0.89%
Quality
13 /100
Poor ROIC 2.48%
Asset turnover 0.68x
ROE 1.68%
Debt
25 /100
High Debt/Equity 1.26x
Net debt/EBITDA 7.16x
Current ratio 1.43x
Stability
26 /100
Unstable Beta 0.60x
Profitable years 0
Rev. volatility 91.82%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about TLX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Christian Behrenbruch
Employees
1,152
Headquarters
North Melbourne
Upcoming events
19 FEB
Earnings
Upcoming earnings report